Le Lézard
Classified in: Science and technology
Subjects: Product/Service, Webcast

ON24 Unveils a Powerful AI Engine Based on First-Party Digital Engagement Data to Help Enterprises Generate Content, Scale Personalization and More


ON24 (NYSE: ONTF), a leading digital engagement platform that drives pipeline and revenue growth, today announced the launch of an AI engine that powers platform innovations to help enterprises use AI to generate content, scale personalized experiences, orchestrate actions, analyze audience behavior and surface prospect buying intent.

Built on the ON24 platform's foundation of first-party digital engagement data, the ON24 AI engine uses millions of human interactions gathered from over a decade of digital experiences to enable businesses to benefit from the efficiency of AI, without losing the authenticity of their brand. This helps companies to optimize their go-to-market resources and performance, while maximizing prospect engagement and revenue growth.

"In today's digital-first world, the companies with the best B2B buying experiences will win. AI has tremendous potential to transform digital marketing and selling, but only if the human aspect is maintained," said Sharat Sharan, co-founder and CEO, ON24. "Our vision is to bring AI together with human engagement to help businesses cost-effectively grow pipeline and revenue without losing their brand's unique differentiation."

Leveraging the latest in generative AI techniques and fine-tuned for B2B sales and marketing, the ON24 AI engine is built for organizations to drive more engagement, take more intelligent actions, automate and streamline processes, and realize continuous ROI. Highlights include the ability to:

"AI has brought us to a critical inflection point for business today, with tremendous potential to help organizations drive more revenue growth with fewer resources," said Jayesh Sahasi, EVP of Product and CTO. "With the launch of the ON24 AI engine, including the new GPT-powered capabilities, we believe our platform will help enterprise B2B sales and marketing teams across industries to further accelerate their shift to a digital-first engagement strategy."

You can learn more about the ON24 digital engagement platform by visiting ON24.com or joining the upcoming webinar, Q1 2023 Platform Innovation: Scaling Human Engagement in an AI-driven World.

About ON24

ON24 is on a mission to re-imagine how companies engage, understand and build relationships with their audience in a digital world. Through our leading sales and marketing platform for digital engagement, businesses use our portfolio of webinar, virtual event and content experiences to drive engagement and generate first-party data, delivering revenue growth across the enterprise ? from demand generation to customer success to partner enablement.

ON24 powers digital engagement for industry-leading customers worldwide, including 3 of the 5 largest global technology companies, 3 of the 6 largest US banks, 3 of the 5 largest global healthcare companies, and 3 of the 5 largest global industrial manufacturers, enabling organizations to reach millions of professionals a month for billions of engagement minutes per year with all the first-party data being captured, generated and integrated from one place. ON24 is headquartered in San Francisco with global offices in North America, EMEA, and APAC. For more information, visit www.ON24.com.

Forward-Looking Statements

This document contains "forward-looking statements" under applicable securities laws. In some cases, such statements can be identified by words such as: "expect," "convert," "believe," "plan," "future," "may," "should," "will," and similar references to future periods. Forward-looking statements include express or implied statements regarding our ability to achieve our business strategies, growth, or other future events or conditions. Such statements are based on our current beliefs, expectations, and assumptions about future events or conditions, which are subject to inherent risks and uncertainties, including the risks and uncertainties discussed in the filings we make from time to time with the Securities and Exchange Commission. Actual results may differ materially from those indicated in forward-looking statements, and you should not place undue reliance on them. All statements herein are based only on information currently available to us and speak only as of the date hereof. Except as required by law, we undertake no obligation to update any such statement.

© 2023 ON24, Inc. All rights reserved. ON24 and the ON24 logo are trademarks owned by ON24, Inc., and are registered in the United States Patent and Trademark Office and in other countries.


These press releases may also interest you

at 07:15
Draganfly Inc. ("Draganfly" or the "Company"), an award-winning, industry-leading drone solutions and systems developer is pleased to announce a strategic collaboration with ParaZero Technologies Ltd., a pioneer in drone safety systems aimed at...

at 07:10
Science Corporation ("Science"), a leader in brain-computer interface ("BCI") technology and the developer of the Science Eye, has acquired the IP and related assets for the PRIMA retinal implant, developed by Pixium Vision SA ("Pixium") of France, a...

at 07:07
MESCIUS inc., a global provider of award-winning enterprise software development tools, is pleased to announce the Document Solutions v7.1 release. This release introduces features and enhancements to MESCIUS's server-side document APIs, JavaScript...

at 07:05
GlycoMimetics, Inc. , today announced that it will host a conference call and webcast to report first quarter 2024 financial results on Thursday, May 9, 2024 at 8:30 a.m. ET. To access the call by phone, please go to this registration link and you...

at 07:05
Harrow , a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the first quarter ended March 31, 2024, on Monday, May 13, 2024, after the market close. The Company will also post its first...

at 07:05
Mind Medicine (MindMed) Inc. , (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present detailed results from its phase 2b study...



News published on and distributed by: